Scholarlink

<p>The development of antibody–drug conjugates for cancer therapy has shown great potential in improving targeted treatment efficacy. This study explores the conjugation of daratumumab, a monoclonal antibody targeting CD38, with protoporphyrin IX and subsequent radiolabeling with terbium-161 (<sup>161</sup>Tb) for potential use as a targeted immunotherapeutic agent in multiple myeloma. The conjugation process involves stable linkage to retain the therapeutic properties of daratumumab, and <sup>161</sup>Tb radiolabeling offers enhanced cytotoxicity through localized beta-emission and Auger electron effects. In vitro studies demonstrate significant inhibition of myeloma cell growth and increased apoptosis, providing a foundation for further preclinical investigation of this conjugate as a targeted radionuclide therapy in hematologic malignancies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Radiolabeling of protoporphyrin-daratumumab conjugate with 161Tb as a CD38 immunotherapeutic agent for multiple myeloma

  • 期刊论文

  • 发表日期：

    2025年11月15日

查看全文
  • Mohamed A. Gizawy,
  • Hanan M. El-Shershaby,
  • E. H. Borai,
  • Hesham A. Shamsel-Din

摘要

The development of antibody–drug conjugates for cancer therapy has shown great potential in improving targeted treatment efficacy. This study explores the conjugation of daratumumab, a monoclonal antibody targeting CD38, with protoporphyrin IX and subsequent radiolabeling with terbium-161 (161Tb) for potential use as a targeted immunotherapeutic agent in multiple myeloma. The conjugation process involves stable linkage to retain the therapeutic properties of daratumumab, and 161Tb radiolabeling offers enhanced cytotoxicity through localized beta-emission and Auger electron effects. In vitro studies demonstrate significant inhibition of myeloma cell growth and increased apoptosis, providing a foundation for further preclinical investigation of this conjugate as a targeted radionuclide therapy in hematologic malignancies.